Buhmann, R., Michael, S., Juergen, H., Horst, L., Peschel, C., & Kolb, H. (2013). Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: Study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. BioMed Central.

Buhmann, Raymund, Stanglmaier Michael, Hess Juergen, Lindhofer Horst, Christian Peschel, and Hans-Jochem Kolb. Immunotherapy With FBTA05 (Bi20), a Trifunctional Bispecific Anti-CD3 X Anti-CD20 Antibody and Donor Lymphocyte Infusion (DLI) in Relapsed or Refractory B-cell Lymphoma After Allogeneic Stem Cell Transplantation: Study Protocol of an Investigator-driven, Open-label, Non-randomized, Uncontrolled, Dose-escalating Phase I/II-trial. BioMed Central, 2013.

Buhmann, Raymund, et al. Immunotherapy With FBTA05 (Bi20), a Trifunctional Bispecific Anti-CD3 X Anti-CD20 Antibody and Donor Lymphocyte Infusion (DLI) in Relapsed or Refractory B-cell Lymphoma After Allogeneic Stem Cell Transplantation: Study Protocol of an Investigator-driven, Open-label, Non-randomized, Uncontrolled, Dose-escalating Phase I/II-trial. BioMed Central, 2013.